Inaugural talk
Date: Monday, 1 August 2022
Time: 18:00-19:00
| The pathway of visceral leishmaniasis elimination: lessons learnt for a huger challenge Jorge Alvar, Senior Advisor and Former Head of Leishmaniasis, DNDi |
Plenary address
Date: Tuesday, 2 August 2022
Time: 8:00-9:00
| Fighting a chronic crisis in access and innovation: The role of DNDi in the development and delivery of treatments for leishmaniasis Bernard Pécoul, Executive Director, DNDi |
Special meeting
The NTDs in the landscape of global health, the view of the world’s opinion leaders
Sponsored by DNDi
Date: Tuesday, 2 August 2022
Time: 14:00-15:30
Room: Cartagena
Chairs: Jorge Alvar, Senior Advisor and Former Head of Leishmaniasis, DNDi and Iván D. Vélez, PECET-Universidad de Antioquia, Colombia
Welcome remarks: Ren Minghui, WHO, Switzerland
Speakers:
- Ren Minghui, WHO, Switzerland
- Peter Hotez, Baylor College of Medicine, USA
- Bernard Pécoul, Executive Director, DNDi
- Kayla Laserson, The Bill and Melinda Gates Foundation, India
Symposia and roundtables
Role of asymptomatics in transmission of leishmanaisis, sleeping sickness and Chagas disease
Date: Tuesday, 2 August 2022
Time: 10:00-11:30
Room: Bolivar – A
Chairs: Maria Jesús Pinazo, Head of Chagas disease, DNDi and Rafael Antonio Herazo Tapia, Chagas Medical Focal Point, DNDi
| Towards visceral leishmaniasis control. New diagnosis approaches to detect asymptomatic patients. Eugenia Carrillo, Instituto de Salud Carlos III, Spain |
| Asymptomatic infections in Human African Trypanosomiasis: Is it a challenge for elimination? Philippe Neau, Sanofi, France |
| Clinical and epidemiological implications of people with T. cruzi infection without organ involvement Maria Jesús Pinazo, Head of Chagas disease, DNDi |
Eliminating visceral leishmaniasis as a public health problem in the WHO South-East Asia Region: the last mile challenges and opportunities through the new Regional Strategy
Sponsored by WHO SEARO
Date: Tuesday, 2 August 2022
Time: 10:00-11:30
Room: Bolivar – D
Panel discussion on Partnerships, innovation needs and advocacy for acceleration to reach and sustain the elimination targets in South-East Asia
Chairs: Saurabh Jain, WHO Geneva and Aya Yajima, WHO-SEARO
Panelists:
- Suman Rijal, WHO-SEARO
- Tanu Jain, National Center for Vector Borne Disease Control, Ministry of Health & Family Welfare, India
- Fabiana Alves, NTD Leishmaniasis-Mycetoma Cluster Director, DNDi
- Shyam Sundar , Banaras Hindu University, India
- Megha Raj Banjara, Central Department of Microbiology, Tribhuvan University, Nepal
Innovation in R&D to contribute to visceral leishmaniasis elimination
Sponsored by DNDi
Date: Tuesday, 2 August 2022
Time: 11:30-13:00
Room: Bolivar – B
Chairs: Fabiana Alves, NTD Leishmaniasis-Mycetoma Cluster Director, DNDi and Gustavo Romero, Universidade de Brasilia, Brazil
| Current context of VL control and elimination in the endemic regions, patients’ needs and the development of new therapies Fabiana Alves, NTD Leishmaniasis-Mycetoma Cluster Director, DNDi |
| Future oral treatments for Visceral Leishmaniasis: LXE408, from discovery to first study in patients Florencia Segal, Novartis Institutes for BioMedical Research, Switzerland |
| PK/PD modeling to optimize treatment regimens for VL Thomas Dorlo, Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital, Netherlands |
| Bringing the treatment closer to the communities: test and treat approach by combining a point of care diagnostics with the new oral safe drugs Israel Cruz, National School of Public Health, CIBERINFEC, Instituto de Salud Carlos III, Spain |
| PKDL treatment – why it is important for VL control and elimination, and the need for improved treatments Shyam Sundar, Institute of Medical Sciences, Banaras Hindu University, India |
Drug target identification, validation, and drug discovery
Date: Wednesday, 3 August 2022
Time: 11:30-13:00
Room: Bolivar – C
Chair: Gerald Spaeth, Institut Pasteur, France
| Current status and future opportunities for drug discovery for leishmaniasis Charles Mowbray, Discovery Director, DNDi |
| A structure-based drug discovery program targeting leishmania glycogen synthase kinase 3 Jadel Müller Kratz, Senior Discovery & R&D Partnerships Manager, DNDi |
| The use of multiple orthogonal methodologies to determine the mechanism of action of promising anti-leishmanial compounds Marta Lopes Lima, University of Dundee, UK |
| The macrophage lysine demethylase lsd1 as a potential target for host-directed antileishmanial drug discovery Maria Gutierrez-Sanchez, Institut Pasteur/Université Paris-Saclay, France |
| Kinetoplastid drug discovery aided by computational science and artificial intelligence Srinivasa Rao, Novartis Institute for Tropical Diseases, USA |
The LEAP – an ongoing experience
Sponsored by DNDi
Date: Wednesday, 3 August 2022
Time: 14:00-15:00
Room: Cartagena
Chair: Monique Wasunna, Eastern Africa Director, DNDi
| The impact of VL in the health agenda, a perspective from the Kenya Ministry of Health Sultani Matendechero, Ministry of Health, Kenya |
| A new strategy for treating VL in Eastern Africa, the PM-MIL combination Ahmed Musa, University of Khartoum, Sudan |
| Cutaneous Leishmaniasis in Eastern Africa, why it should no longer be neglected Endalamaw Gadisa Belachew, Armauer Hansen Research Institute, Ethiopia |
| The LEAP, from a research platform towards access Simon Bolo, Head of Leishmaniasis Access, DNDi |
Lessons learnt in visceral leishmaniasis elimination, progress, and perspectives
Date: Wednesday, 3 August 2022
Time: 14:00-15:00
Room: Bolivar – B
Chairs: Nirmal Kumar Ganguly, National Academy of Medical Sciences, India and Daniel Argaw Dagne WHO, Switzerland
| Overview of leishmaniasis control/elimination: progress to date Daniel Argaw Dagne, WHO, Switzerland |
| Diagnostics in leishmaniasis: key advances, unmet needs and limitations Israel Cruz, Instituto de Salud Carlos III, Spain |
| Headway and Gaps in Innovative Vector Control Approaches suited to Eco-Epidemiological Settings Dia-Eldin Elnaiem, University of Maryland Eastern Shore, USA |
| Treatment in visceral and cutaneous leishmaniasis: advances, gaps and challenges Fabiana Alves, NTD Leishmaniasis-Mycetoma Cluster Director, DNDi |
| Partners perspective for VL control/elimination support Jordan Tappero, Bill and Melinda Gates Foundation |
| Perspectives of the global leishmaniasis control/elimination in line with NTD roadmap 2030 Saurabh Jain,WHO, Switzerland |
Future prospects in the treatment of cutaneous leishmaniasis form
Sponsored by DNDi
Date: Thursday, 4 August 2022
Time: 10:00-11:30
Room: Bolivar – A
Chairs: Byron Arana, Head of Cutaneous Leishmaniasis Disease, DNDi and Max Grogl, Naval Medical Research Center, USA
| Is there a place for immunomodulators in the treatment of CL? Paulo Roberto Lima Machado, Universidade Federal da Bahia, Brazil |
| Building the pathway for translational drug development of orally active new chemical entities for cutaneous leishmaniasis Jadel Müller Kratz, Senior Discovery & R&D Partnerships Manager, DNDi |
| Topical paromomycin in cutaneous leishmaniasis: supportive clinical data and a regulatory roadmap Armand Balboni, US Air Force Academy; Appili Therapeutics |
| Unmet needs in cutaneous leishmaniasis diagnosis and 2030 Road Map Targets Israel Cruz, Instituto de Salud Carlos III, Spain |
Biomarkers for diagnosis of leishmaniasis
Date: Thursday, 4 August 2022
Time: 10:00-11:30
Room: Bolivar – C
Chair: Eugenia Carrillo, Instituto de Salud Carlos III, Spain
| Biomarkers in visceral leishmaniasis patients coinfected with HIV Wim Adriaensen, Institute of Tropical Medicine Antwerp, Belgium |
| Biomarkers in PKDL Ed Zijlstra, Rotterdam Center for Tropical Medicine, Netherlands; and Consultant Expert Mycetoma/PKDL, DNDi |
| Diagnosis of visceral leishmaniasis in an elimination setting: a validation study of the diagnostic algorithm in India Shyam Sundar, Institute of Medical Sciences, Banaras Hindu University, India |
A global visceral leishmaniasis data platform
Sponsored by IDDO
Date: Thursday, 4 August 2022
Time: 11:30-13:00
Room: Bolviar – B
Chair: Philippe Guérin, University of Oxford, UK
| Key challenges and opportunities Mitali Chatterjee, Institute of Postgraduate Medical Education & Research, India |
| Optimising historical data and planning prospectively Ahmed Musa, University of Khartoum, Sudan |
| Data platform potential for drug development Fabiana Alves, NTD Leishmaniasis-Mycetoma Cluster Director, DNDi |
| Impact on policy Saurabh Jain, WHO, Switzerland |
| Future benefits of the VL Data Platform for research Philippe Guérin, University of Oxford, UK |
Successful experience
Date: Friday, 5 August 2022
Time: 9:00-9:30
Speaker: Fabiana Alves, NTD Leishmaniasis-Mycetoma Cluster Director, DNDi
New hope for leishmaniasis: how to communicate to a broader non-scientific audience
Date: Friday, 5 August 2022
Time: 10:00-11:30
Room: Guacamayo
Chair: Marcela Dobarro, Regional Communications Manager, DNDi, Latin America
| A storytelling approach to social determinants of health related to leishmaniasis Marcela Dobarro, Regional Communications Manager, DNDi, Latin America |
| Strategic dissemination of research results: promoting positive impact on the population Ximena Serrano Gil, Colombian Association of Journalism and Science Communication, World Federation of Science Journalism, Colombia |
| Health and inequalities: a story of coca deforestation and leishmaniasis Efrain Rincón Alves, Colombia |
| Telling the story of leishmaniasis and war in Colombia: a book, a exhibit, and a policy brief Lina Pinto-García, Institute for Science, Innovation and Society (InSIS) – University of Oxford, Interdisciplinary Center for Development Studies (CIDER) – Universidad de los Andes, Colombia |
Drug resistance & quiescence: unravelling mechanisms and exploitation for better/new drugs
Date: Friday, 5 August 2022
Time: 11:30-13:00
Room: Bolivar – A
Chair: Jean-Claude Dujardin, Institute of Tropical Medicine of Antwerp, Belgium
| Genomic screens for drug resistance studies in Leishmania Marc Ouellette, Université Laval, Canada |
| Unraveling quiescent phenotypes as an adaptation to overcome drug pressure in Leishmania Marlene Jara, Institute of Tropical Medicine of Antwerp, Belgium |
| Tackling persisters in Chagas disease drug discovery Manu De Rycker, University of Dundee, UK |
| Exploiting knowledge on drug resistance and tolerance in R&D for new drugs Jadel Müller Kratz, Senior Discovery & R&D Partnerships Manager, DNDi |
Visceral leishmaniasis elimination programme in Africa: Envisioning the stakeholders perspective
Sponsored by The END Fund
Date: Friday, 5 August 2022
Time: 14:00-15:30
Room: Bolivar – C
Chairs: Jorge Alvar, Senior Advisor and Former Head of Leishmaniasis, DNDi and Carol Karutu, The END Fund, Kenya
Speakers:
- Daniel Argaw, WHO, Switzerland
- Koert Ritmeijer, MSF, Netherlands
- Margaret Anyetei Agama, Social Affairs, African Union Commission, Ethiopia
- Duncan Ochol, The END Fund, Kenya
- Bhupendra Tripathi , Infectious Diseases Cluster, India Country Office, The Bill and Melinda Gates Foundation
